<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="29623"><DrugName>ataciguat</DrugName><DrugNamesKey><Name id="42832437">ataciguat</Name></DrugNamesKey><DrugSynonyms><Name><Value>1766</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HMR-1766</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HMR-1766A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ataciguat</Value><Types><Type>INN</Type></Types></Name><Name><Value>254877-67-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25218">Aventis Pharma AG</CompanyOriginator><CompaniesPrimary><Company id="1009547">Sanofi SA</Company></CompaniesPrimary><CompaniesSecondary><Company id="25218">Aventis Pharma AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="29623" type="Drug"><TargetEntity id="343470" type="siDrug">Ataciguat</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="25218" type="Company"><TargetEntity id="4296758779" type="organizationId">Aventis Pharma AG</TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"></TargetEntity><TargetEntity id="D009437" type="MeSH"></TargetEntity><TargetEntity id="-533466818" type="omicsDisease"></TargetEntity><TargetEntity id="14" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1565" type="ciIndication"><TargetEntity id="10002918" type="MEDDRA"></TargetEntity><TargetEntity id="D001024" type="MeSH"></TargetEntity><TargetEntity id="-1111112887" type="omicsDisease"></TargetEntity><TargetEntity id="1850" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1598" type="ciIndication"><TargetEntity id="10062585" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1867" type="ciIndication"><TargetEntity id="10037400" type="MEDDRA"></TargetEntity><TargetEntity id="D006976" type="MeSH"></TargetEntity><TargetEntity id="-104458654" type="omicsDisease"></TargetEntity><TargetEntity id="243" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="23" type="ciIndication"><TargetEntity id="I20" type="ICD10"></TargetEntity><TargetEntity id="10002383" type="MEDDRA"></TargetEntity><TargetEntity id="D000787" type="MeSH"></TargetEntity><TargetEntity id="-1965112918" type="omicsDisease"></TargetEntity><TargetEntity id="223" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="492" type="Action"><TargetEntity id="528" type="Mechanism">Guanylate Cyclase Activators</TargetEntity><TargetEntity id="5055" type="Mechanism">Soluble Guanylate Cyclase (sGC) Activators</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><IndicationsPrimary><Indication id="1565">Aortic valve stenosis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1295">Neuropathic pain</Indication><Indication id="1598">Peripheral arterial occlusive disease</Indication><Indication id="1867">Pulmonary hypertension</Indication><Indication id="23">Angina</Indication></IndicationsSecondary><ActionsPrimary><Action id="492">Guanylate cyclase stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="2660">Vasoprotectant</Action><Action id="279">Nitric oxide synthesis stimulator</Action><Action id="388">Vasodilator</Action><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-12-16T10:59:15.000Z</LastModificationDate><ChangeDateLast>2016-09-14T00:00:00.000Z</ChangeDateLast><AddedDate>2000-07-13T16:34:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi-aventis&lt;/ulink&gt; (formerly &lt;ulink linkID="27254" linkType="Company"&gt;Aventis&lt;/ulink&gt;) is developing ataciguat (HMR-1766, 1766), an oral guanylate cyclase activator which induces the intracellular production of nitric oxide (NO), for the potential treatment of  aortic valve stenosis. In January 2014, a phase Ib study was initiated [&lt;ulink linkID="1536765" linkType="Reference"&gt;1536765&lt;/ulink&gt;]. In June 2015, a phase II trial was   initiated   [&lt;ulink linkID="1674548" linkType="Reference"&gt;1674548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was also developing ataciguat for peripheral arterial occlusive disease (PAOD)  [&lt;ulink linkID="374409" linkType="Reference"&gt;374409&lt;/ulink&gt;]. By September 2007, it was in phase IIb studies for PAOD [&lt;ulink linkID="830785" linkType="Reference"&gt;830785&lt;/ulink&gt;]. However, by February 2009, development had been terminated for this indication [&lt;ulink linkID="983055" linkType="Reference"&gt;983055&lt;/ulink&gt;].The company was also developing ataciguat for pulmonary arterial hypertension (PAH). By February 2006, phase IIa studies had been initiated but by September 2007, this indication was no longer  listed  [&lt;ulink linkID="830785" linkType="Reference"&gt;830785&lt;/ulink&gt;]. Sanofi-aventis was additionally developing ataciguat for chronic angina. By March 2005, phase IIa studies had been initiated but by February 2006, this indication was no longer listed [&lt;ulink linkID="652672" linkType="Reference"&gt;652672&lt;/ulink&gt;]. The company was also developing ataciguat neuropathic pain.  A phase II trial began in November 2008 [&lt;ulink linkID="969191" linkType="Reference"&gt;969191&lt;/ulink&gt;]. However, by February 2010, development for neuropathic pain had been terminated [&lt;ulink linkID="1074290" linkType="Reference"&gt;1074290&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sanofi-aventis was also developing &lt;ulink linkID="40162" linkType="Drug"&gt;HMR-1069&lt;/ulink&gt;  as a back-up for ataciguat. In June 2002, Aventis revealed that the better of the two drugs was to be progressed into phase II studies [&lt;ulink linkID="455004" linkType="reference"&gt;455004&lt;/ulink&gt;]; as of  February 2008, HMR-1069 was no longer listed in the sanofi-aventis pipeline.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Aaortic valve stenosis&lt;/subtitle&gt;In June 2015, a randomized, single group assignment, double blind, phase II trial (&lt;ulink linkID="233272" linkType="Protocol"&gt;NCT02481258&lt;/ulink&gt;; 14-006469, TR 000954) was planned to be initiated in the US to evaluate the effects of ataciguat on aortic valve calcification in patients (estimated n = 100) with moderate calcific aortic valve stenosis. At that time, the trial was expected to complete in May 2017 [&lt;ulink linkID="1674548" linkType="Reference"&gt;1674548&lt;/ulink&gt;]. Later that month, the trial was initiated  [&lt;ulink linkID="1674548" linkType="Reference"&gt;1674548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, a phase Ib randomized, placebo-controlled, double-blinded  study (&lt;ulink linkID="170775" linkType="Protocol"&gt;NCT02049203&lt;/ulink&gt;; 13-005387) was initiatedin patients (expetced n = 40) with moderate calcific aortic valve stenosis in the US; at that time, the study was expected to complete in January 2015 [&lt;ulink linkID="1536765" linkType="Reference"&gt;1536765&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pain&lt;/subtitle&gt;In November 2008, a randomized, double-blind, placebo-controlled, phase II, safety and efficacy study (&lt;ulink linkID="37494" linkType="Protocol"&gt;NCT00799656&lt;/ulink&gt;; DFI10569, EudraCT 2008-001518-26) began in Romania which would assess the effect of oral ataciguat (200 mg once-daily for 28 days) on average daily pain intensity in 60 patients with neuropathic pain due to diabetic polyneuropathy or a nerve lesion following surgery [&lt;ulink linkID="969191" linkType="Reference"&gt;969191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Peripheral arterial occlusive disease&lt;/subtitle&gt;In March 2007, placebo-controlled, randomized, double-blind phase IIb trial (NCT00443287, DFI6174, ACCELA) was initiated in subjects (expected n = 550) with  PAOD and intermittent claudication in the US, Austria, Canada, France, Poland, Russian Federation and South Africa. The subjects were to receive &lt;ulink linkID="2836" linkType="Drug"&gt;clopidogrel&lt;/ulink&gt; and one of three doses of ataciguat or placebo. Effects were to be calibrated against &lt;ulink linkID="13482" linkType="Drug"&gt;cilostazol&lt;/ulink&gt;. The primary endpoint was percentage change in initial claudication distance measured at the 26-week treadmill test compared to baseline. The study was still recruiting in  March 2008 [&lt;ulink linkID="884837" linkType="Reference"&gt;884837&lt;/ulink&gt;]. In March 2008, results were expected at the end of 2008 [&lt;ulink linkID="884729" linkType="Reference"&gt;884729&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2004, the compound was in phase I or IIa trials [&lt;ulink linkID="521119" linkType="reference"&gt;521119&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2001, phase I trials had demonstrated safety and the compound's long half-life was found suitable for once-daily dosing [&lt;ulink linkID="409257" linkType="reference"&gt;409257&lt;/ulink&gt;]. However in June 2002, Aventis indicated that development of ataciguat had been delayed due to formulation problems. An improved formulation for once-daily oral dosing was in phase I trials and showed no interaction with food [&lt;ulink linkID="455004" linkType="reference"&gt;455004&lt;/ulink&gt;], [&lt;ulink linkID="455054" linkType="reference"&gt;455054&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In July 2000, ataciguat was in phase I/IIa trials and  Aventis predicted product launch to take place in 2005 [&lt;ulink linkID="370971" linkType="reference"&gt;370971&lt;/ulink&gt;], [&lt;ulink linkID="374409" linkType="reference"&gt;374409&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2006, preclinical data were presented at the AHA Scientific Sessions in Chicago, IL. TGF-beta stimulation of cardiac fibroblasts in vitro produced a 250% increase in extracellular matrix production. This was dose-dependently inhibited by ataciguat (0.3 to 10 microM) or an NO donor. It also inhibited differentiation of the cells into myofibroblasts. Therefore ataciguat could be used to inhibit fibrosis and remodeling following myocardial infarction [&lt;ulink linkID="738026" linkType="Reference"&gt;738026&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, preclinical data with ataciguat were presented at the AHA meeting in Dallas, TX.  Apolipoprotein (apo) E-deficient mice were fed a high-fat diet containing 1.25% cholesterol for 6 weeks, or 0.5% cholesterol for 15 weeks, or the respective cholesterol-rich diets supplemented with ataciguat. At the end of the treatment periods, there were no significant differences in plasma cholesterol concentrations between the groups. However, both ataciguat treatment regimens significantly reduced atherosclerotic plaque formation and markedly improved endothelium-dependent vasodilation. It was concluded that this compound is a novel therapeutic agent for the potential treatment of atherosclerosis [&lt;ulink linkID="636556" linkType="Reference"&gt;636556&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Ataciguat is expected to be effective in patients with atherosclerosis and endothelial dysfunction as well as in patients not responding to nitrates [&lt;ulink linkID="409257" linkType="reference"&gt;409257&lt;/ulink&gt;], [&lt;ulink linkID="379340" linkType="reference"&gt;379340&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1565">Aortic valve stenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-06-30T00:00:00.000Z</StatusDate><Source id="1674548" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="RO">Romania</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-02-10T00:00:00.000Z</StatusDate><Source id="1074290" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-02-11T00:00:00.000Z</StatusDate><Source id="983055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="23">Angina</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-02-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1565">Aortic valve stenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-01-31T00:00:00.000Z</StatusDate><Source id="1536765" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="23">Angina</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-06-19T00:00:00.000Z</StatusDate><Source id="455054" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="23">Angina</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-08-20T00:00:00.000Z</StatusDate><Source id="555709" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="23">Angina</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-07-13T00:00:00.000Z</StatusDate><Source id="374409" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="23">Angina</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-03-01T00:00:00.000Z</StatusDate><Source id="587512" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-02-24T00:00:00.000Z</StatusDate><Source id="652672" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-08-31T00:00:00.000Z</StatusDate><Source id="620762" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="RO">Romania</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-11-27T00:00:00.000Z</StatusDate><Source id="969191" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00897"><Name>Guanylate cyclase</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21111">Mayo Clinic Foundation</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1cc(ccc1NC(=O)c2cc(ccc2NS(=O)(=O)c3ccc(s3)Cl)Cl)S(=O)(=O)N4CCOCC4</Smiles></StructureSmiles><Deals><Deal id="155779" title="Mayo Clinic to conduct phase II study of Sanofi's ataciguat against aortic valve stenosis    "></Deal></Deals><PatentFamilies><PatentFamily id="1366539" number="WO-2007025595" title="Use of soluble guanylate cyclase activators for treating reperfusion damage"></PatentFamily><PatentFamily id="1693992" number="WO-2005011727" title="Combination of an activator of soluble guanylate cyclase and an ACE-inhibitor for the treatment of a cardiovascular or metabolic disorder"></PatentFamily><PatentFamily id="2032520" number="WO-2007009589" title="Use of soluble guanylate cyclase for the treatment of Raynaud's phenomenon"></PatentFamily><PatentFamily id="2111856" number="WO-2009043495" title="Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain"></PatentFamily><PatentFamily id="2180406" number="WO-2007009607" title="Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders"></PatentFamily><PatentFamily id="2758229" number="WO-2014100733" title="Methods and materials for treating calcific aortic valve stenosis"></PatentFamily><PatentFamily id="2834669" number="WO-2014190250" title="Activators of soluable guanylate cyclase and their use in treatment of Duchenne muscular dystrophy and related disease"></PatentFamily><PatentFamily id="792763" number="WO-00002851" title="Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Washington" id="20701"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayo Clinic Foundation" id="21111"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kennedy Krieger Institute" id="25533"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>